Effectiveness and Cost-effectiveness of Immediate Versus Delayed Treatment of Hepatitis C Virus-Infected Patients in a Country With Limited Resources: The Case of Egypt

被引:28
|
作者
Obach, Dorothee [1 ,2 ,3 ]
Deuffic-Burban, Sylvie [1 ,2 ,3 ,4 ]
Esmat, Gamal [5 ]
Anwar, Wagida A. [6 ]
Dewedar, Sahar [6 ]
Canva, Valerie [7 ]
Cousien, Anthony [1 ,2 ,3 ]
Doss, Wahid [8 ]
Mostafa, Aya [6 ]
Pol, Stanislas [9 ,10 ]
Buti, Maria [11 ,12 ]
Siebert, Uwe [13 ,14 ]
Fontanet, Arnaud [15 ,16 ]
Mohamed, Mostafa K. [6 ]
Yazdanpanah, Yazdan [1 ,2 ,17 ]
机构
[1] INSERM, IAME, UMR 1137, F-75018 Paris, France
[2] Univ Paris Diderot, Sorbonne Paris Cite, F-75018 Paris, France
[3] Univ Lille Nord France, EA2694, Lille, France
[4] Univ Lille Nord France, INSERM, U995, Lille, France
[5] Cairo Univ, Fac Med, Dept Trop Med, Cairo, Egypt
[6] Ain Shams Univ, Fac Med, Dept Community Environm & Occupat Med, Cairo, Egypt
[7] CHRU Lille, Hop Huriez, Serv Malad Appareil Digestif & Nutr, Lille, France
[8] Natl Hepatol & Trop Med Res Inst, Cairo, Egypt
[9] Univ Paris 05, Unite Hepatol, Grp Hosp Cochin Hotel Dieu, Paris, France
[10] INSERM, U1016, Paris, France
[11] Hosp Gen Univ Valle Hebron, Dept Internal Med, Liver Unit, Barcelona, Spain
[12] Inst Carlos III, Ciber Ehd, Barcelona, Spain
[13] Univ Hlth Sci, UMIT, Hall In Tirol, Austria
[14] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA
[15] Hop Bichat Claude Bernard, Inst Pasteur, Emerging Dis Epidemiol Unit, F-75877 Paris 18, France
[16] Hop Bichat Claude Bernard, Chaire Dev & Sante, Conservatoire Natl Arts & Metiers, F-75877 Paris 18, France
[17] Hop Bichat Claude Bernard, Serv Malad Infect & Trop, F-75877 Paris 18, France
关键词
HCV; cost-effectiveness; resource-limited countries; Egypt; antiviral treatment; SUSTAINED VIROLOGICAL RESPONSE; QUALITY-OF-LIFE; VIRAL RESPONSE; FIBROSIS; PROGRESSION; MORBIDITY; RIBAVIRIN; CIRRHOSIS; GENOTYPE;
D O I
10.1093/cid/ciu066
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Because of logistical and economic issues, in Egypt, as in other resource-limited settings, decision makers should determine for which patients hepatitis C virus (HCV) treatment should be prioritized. We assessed the effectiveness and cost-effectiveness of different treatment initiation strategies. Methods. Using a Markov model, we simulated HCV disease in chronically infected patients in Egypt, to compare lifetime costs, quality-adjusted life expectancy (QALE), and the incremental cost-effectiveness ratio (ICER) of different treatment initiation strategies. Results. Immediate treatment of patients at stages F1/F2/F3 was less expensive and more effective than delaying treatment until more severe stages or not providing treatment (in patients diagnosed at F1: QALE = 18.32 years if treatment at F1 vs 18.22 if treatment at F2). Treatment of F4 patients was more effective than no treatment at all (QALE = 10.33 years vs 8.77 years) and was cost-effective (ICER = $1915/quality-adjusted life-year [ QALY]). When considering that affordable triple therapies, including new direct-acting antivirals, will be available starting in 2016, delaying treatment until stage F2, then treating all patients regardless of their disease stage after 2016, was found to be cost-effective (ICER = $33/QALY). Conclusions. In Egypt, immediate treatment of patients with fibrosis stage F1-F3 who present to care is less expensive and more effective than delaying treatment. However, immediate treatment at stage F1 is only slightly more effective than waiting for disease to progress to stage F2 before starting treatment and is sensitive to the forthcoming availability of new treatments. Treating patients at stage F4 is highly effective and cost-effective. In Egypt, decision makers should prioritize treatment for F4 patients and delay treatment for F1 patients who present to care.
引用
收藏
页码:1064 / 1071
页数:8
相关论文
共 50 条
  • [31] Cost-effectiveness of interferon treatment for hepatitis C - Reply
    Wong, JB
    Koff, RS
    Pauker, SG
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (22): : 2084 - 2084
  • [33] The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C
    Myers, RP
    Gregor, JC
    Marotta, PJ
    HEPATOLOGY, 2000, 31 (04) : 834 - 839
  • [34] Cost-effectiveness of treatment for chronic hepatitis C infection
    Bernstein, D
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (15): : 1993 - 1993
  • [35] Cost-effectiveness of chronic hepatitis C treatment in Spain
    Haj-Ali Saflo, Okba
    Hernandez Guijo, Jesus Miguel
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2009, 32 (07): : 472 - 482
  • [36] Cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C
    Jacobs, RJ
    Koff, RS
    HEPATOLOGY, 2000, 32 (04) : 873 - 874
  • [37] Cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C
    Myers, RP
    Gregor, JC
    Marotta, PJ
    GASTROENTEROLOGY, 1999, 116 (04) : A1252 - A1252
  • [38] Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV
    Campos, Nicole G.
    Salomon, Joshua A.
    Servoss, Julie C.
    Nunes, David P.
    Samet, Jeffrey H.
    Freedberg, Kenneth A.
    Goldie, Sue J.
    AMERICAN JOURNAL OF MEDICINE, 2007, 120 (03): : 272 - 279
  • [39] Cost-effectiveness of elective cesarean delivery in human immunodeficiency virus-infected women
    Chen, KT
    Sell, RL
    Tuomala, RE
    OBSTETRICS AND GYNECOLOGY, 2001, 97 (02): : 161 - 168
  • [40] Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C
    Sroczynski, G.
    Esteban, E.
    Conrads-Frank, A.
    Schwarzer, R.
    Muehlberger, N.
    Wright, D.
    Zeuzem, S.
    Siebert, U.
    JOURNAL OF VIRAL HEPATITIS, 2010, 17 (01) : 34 - 50